Polymorphisms in the interleukin 6 and transforming growth factor β1 gene and risk of dementia: The Rotterdam Study
Section snippets
Acknowledgements
This study was supported by the Netherlands Organization for Scientific Research (NWO grant 904-61093) and by the European Commission (grant QLK6-CT-2002 02629, “GENOMOS”).
The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam, The Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture
References (37)
- et al.
Inflammation and Alzheimer's disease
Neurobiol. Aging
(2000) - et al.
Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease
Neurobiol. Aging
(2004) - et al.
Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease
Neurosci. Lett.
(2000) - et al.
Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe
Exp. Gerontol.
(2004) - et al.
“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
J. Psychiatr. Res.
(1975) - et al.
Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain
Neurobiol. Aging
(2003) - et al.
Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease
Brain Res. Brain Res. Rev.
(1997) - et al.
Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer's disease
Neurosci. Lett.
(2004) - et al.
A new statistical method for haplotype reconstruction from population data
Am. J. Hum. Genet.
(2001) - et al.
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation
J. Biol. Chem.
(2000)
Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: the Honolulu-Asia Aging Study
Neurobiol. Aging
Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease
Neurosci. Lett.
Association study of three polymorphisms of TGF-beta1 gene with Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry
Consistency of epidemiologic estimates
Eur. J. Epidemiol.
Transgenic models to assess the pathogenic actions of cytokines in the central nervous system
Mol. Psychiatry
Serum cytokine levels in patients with Alzheimer's disease
Clin. Diagn. Lab. Immunol.
A semi-structured clinical interview for the assessment of diagnosis and mental state in the elderly: the Geriatric Mental State Schedule. I. Development and reliability
Psychol. Med.
Cited by (41)
The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders
2017, NeuropharmacologyCitation Excerpt :Expression of neuronal type-II TGF-β receptors is reduced in the AD brain, and dysfunction of TGF-β signaling causes AD pathology and neurodegeneration in mice (Das and Golde, 2006; Tesseur et al., 2006; reviewed by Caraci et al., 2012). The link between TGF-β and AD is strengthened by the association between AD and TGF-β1 gene polymorphism (Luedecking et al., 2000; Dickson et al., 2005; Arosio et al., 2007; Caraci et al., 2012; Bosco et al., 2013; but see also Araria-Goumidi et al., 2002; Rodríguez-Rodríguez et al., 2007; van Oijen et al., 2006; and Chang et al., 2013 for lack of association). mGlu3 receptor PAMs might be promising candidates as disease-modifiers in the treatment of AD because they are expected to stimulate the production of TGF-β, rescue memory deficits, and induce neuroprotection (reviewed by Bruno et al., 2001).
Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysis
2016, Meta GeneCitation Excerpt :Three studies (Fontalba et al., 2009, Combarros et al., 2005 and Infante et al., 2004) provided deficient genotype data. Also, the genotype data presented by van Oijen et al.'s (2006) group may overlap with that of Combarros et al. 2010 (Rotterdam study). However, the Qi et al. meta-analysis included these four studies.
Genetic and environmental determinants of population variation in interleukin-6, its soluble receptor and C-reactive protein: Insights from identical and fraternal twins
2015, Brain, Behavior, and ImmunityCitation Excerpt :However, this general conclusion is often, and inappropriately, overgeneralized to all aspects of IL-6 synthesis and release. In the absence of inflammatory stimuli, SNPs have a weak or no association with baseline levels of IL-6 in the blood stream (Bagli et al., 2003; Bennermo et al., 2004; Brull et al., 2001; Burzotta et al., 2001; Herbert et al., 2006; Lieb et al., 2004; Nauck et al., 2002; Sen et al., 2011; Shah et al., 2013; van Oijen et al., 2006; Wernstedt et al., 2004). On the other hand, SNPs affecting sIL-6r production appear to be more consistently associated with its levels in systemic circulation (Galicia et al., 2004; Rafiq et al., 2007; Sasayama et al., 2012; van Dongen et al., 2014).
The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression
2012, European NeuropsychopharmacologyInterleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease in Caucasians: A meta-analysis
2011, Neuroscience Letters